Safety and Efficacy Study of DCVax-Direct in Solid Tumors
This study is currently recruiting participants.
Verified January 2014 by Northwest Biotherapeutics
Information provided by (Responsible Party):
First received: June 14, 2013
Last updated: January 24, 2014
Last verified: January 2014
The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct into selected solid tissue tumors has the ability to reduce tumor growth.
Locally Advanced Tumor
Metastatic Solid Tissue Tumors
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Primary Outcome Measures:
- Number of patients with adverse events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Number of patients with tumor response [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Other Outcome Measures:
- Number of patients surviving [ Time Frame: 24 months ] [ Designated as safety issue: No ]
- Number of patients surviving without tumor progression [ Time Frame: 24 months ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||June 2015 (Final data collection date for primary outcome measure)
DCVax-Direct: autologous, activated dendritic cells for intratumoral injection
Autologous, activated dendritic cells for intratumoral injection
|Ages Eligible for Study:
||18 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria (summary):
- Age between 18 and 75 years (inclusive) at screening.
- Karnofsky performance status (KPS) of 60 or higher or Eastern Cooperative Oncology Group (ECOG) 0-2 at screening.
- Patients with a histological or cytopathological confirmed diagnosis of a locally advanced or metastatic solid tumor malignancy for which standard treatment is no longer effective or does not offer curative or life-prolonging potential per clinician judgment.
- Not eligible for complete resection due to either, tumor location, physician's assessment or patient's choice.
- Must have completed at least one and no more than four treatment regimens in the metastatic or advanced setting in the disease currently under treatment to reduce tumor burden. Treatment must have been discontinued at least 14 days prior to initiating leukapheresis.
- Any steroid therapy >2 mg dexamethasone or equivalent dose should be stopped or have been tapered down 2 weeks prior to the leukapheresis.
- At least one measurable tumor mass, i.e. a lesion that can accurately be measured by CT/MRI in at least one dimension with longest diameter ≥ 1 cm, that is accessible for injection either with or without imaging (CT/ultrasound) guidance.
- Adequate hematological, hepatic, and renal function,
- Adequate blood coagulation parameters
- Life expectation of >3 months.
Exclusion Criteria (Summary):
- Positive HIV-1, HIV-2, or Human T-lymphotropic virus (HTLV-I/II) tests.
- History of current or prior (within the last two years) active clinically significant malignancy other than the tumor type for which DCVax-Direct treatment is considered , and except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
- Presence of brain metastases, unless treated surgically and/or irradiated and clinically stable off steroids or on low dose (< 2 mg per day) steroids for ≥ 14 days, or presence of leptomeningeal disease.
- History of immunodeficiency or unresolved autoimmune disease.
- Requirement for ongoing immunosuppressants.
- Prior active immunotherapy for cancer within the past 2 years.
- Ongoing medical need for continuous anti-coagulation or anti-platelet medication.
- Known genetic cancer-susceptibility syndromes.
- Acute or active uncontrolled infection
- Ongoing fever ≥ 101.5 degrees F/38.6 degrees C at screening.
- Unstable or severe intercurrent medical conditions such as unstable angina, uncontrolled arrhythmias, Crohn's Disease, ulcerative colitis etc.
- Females of child-bearing potential who are pregnant or lactating or who are not using adequate contraception (surgical, hormonal or double barrier, i.e. condom and diaphragm).
- Allergy or anaphylaxis to any of the reagents used in this study.
- Inability to obtain informed consent because of psychiatric or complicating medical problems.
- Inability or unwillingness to return for required visits and follow-up exams.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01882946
|MD Anderson Cancer Center Orlando
|Orlando, Florida, United States, 32806 |
|Contact: Mollie Geismer, RN, PhD, CCRP 321-841-5206 Mollie.Geismer@orlandohealth.com |
|Contact: Kristine Moore, RN, CCRP 321-841-7612 KristineMDAResearch.Moore@orlandohealth.com |
|Principal Investigator: Omar Kayaleh, MD |
|MD Anderson Cancer Center
|Houston, Texas, United States, 77030 |
|Contact: Babita Saigal, MD 713-745-8618 email@example.com |
|Contact: Patient Access Center 713-792-1160 |
|Principal Investigator: Vivek Subbiah, MD |
||Marnix Bosch, MBA, PhD
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 14, 2013
||January 24, 2014
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 09, 2014
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Endocrine Gland Neoplasms
Endocrine System Diseases